July 18, 2023 07:16 AM EDT

CRO Syneos Health didn't hold up its end of the deal in enrollment for FSD Pharma's trial, arbitration panel finds

Katherine Lewin

News Reporter

The contract research organization Syneos Health didn’t hold up its end of the deal and use “commercially reasonable efforts” when setting up a trial for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CRO Syneos Health didn't hold up its end of the deal in enrollment for FSD Pharma's trial, arbitration panel finds

Katherine Lewin

News Reporter

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

CRO Sy­neos Health did­n't hold up its end of the deal in en­roll­ment for FSD Phar­ma's tri­al, ar­bi­tra­tion pan­el finds

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

CRO Syneos Health didn't hold up its end of the deal in enrollment for FSD Pharma's trial, arbitration panel finds

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy